Autopsy report · NCT04023721

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.

“Safety”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 1 month before it stopped.
64 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: F-star Therapeutics, Inc.
Sponsor type: Industry
Conditions: Hepatitis B; HBV; Hepatitis B, Chronic
Interventions: Inarigivir soproxil; Nucleoside/nucleotide (NUC) analogue inhibitors
Participants: 64
Sites: 7
Countries: Canada, United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.